Drug development

#Covid-19 #Drug development #Drug discovery #Immunology / Virology & Vaccines

Biden to invest US$3 bn to boost Covid-19 drug discovery

As part of the American Rescue Plan, the Biden Administration is investing more than US$3 billion to accelerate the discovery, development and manufacturing of antiviral medicines as part of the whole-of-government strategy to develop the next generation of Covid-19 treatments. Through collaboration within the US Department of Health and Human… Read More

#News #Trending News

#Covid-19 #Drug delivery #Drug development

Corticosteroids could treat Covid-19 complications in children

Corticosteroids may be an effective treatment for children who develop a rare but serious condition after Covid-19 infection. This is the finding of an international study of 614 children, published in the New England Journal of Medicine, led by Imperial College London. All children in the study developed a serious… Read More

#News

#Clinical trials #Drug development #Drug screening #Screening

Sygnature Discovery expands into early CMC development

Sygnature Discovery has announced the set-up of an Early Candidate Developability Screening Group. Located at its headquarters in Nottingham, UK, the new service line will expand on the company’s offerings to customers by bridging into formal preclinical drug development and paving the way for clinical trials. With over £1 million… Read More

#News

#Drug development #Inflammatory Bowel Disease #Microbiology #Microbiome

Funding for new microbiome marker to aid treatment of IBD

Genetic Analysis (GA) has announced that the Norwegian Research Council has approved its grant application of NOK 16 million (€1.6 million) for its project developing new innovative microbiome-based diagnostics to be used to aid selection and treatment of Inflammatory Bowel Disease (IBD) patients. In this project, GA will develop an… Read More

#News

#Drug development #Gene therapy #mRNA #Therapeutics

Evonik to develop new drug delivery platform for mRNA

Evonik is working with Stanford University on a technology to deliver mRNA to tissues and organs that goes beyond the capabilities of lipid nanoparticles (LNPs). Starting in June 2021, Evonik and Stanford scientists begin a three-year sponsored research collaboration to develop the polymer-based drug delivery system, which Evonik will license… Read More

#News

#Biologics #Cell and gene therapy #Drug development

Yposkesi launches construction of its second commercial bioproduction site

Yposkesi, a Contract Development and Manufacturing Organisation (CDMO) specialising in cell and gene therapies, has announced the launch of project SKY, the construction of Yposkesi’s second commercial cell and gene therapy facility and new global resource for drug developers of biologics, also called ATMPs (Advanced Therapy Medicinal Products). ATMPs treat… Read More

#News

#Drug development #Pharma #Pharmatech

Assessing IDMP maturity as the data-driven future takes form

With the latest EU IDMP guidance now published, pharma companies must now measure their readiness for the new world, in which data-based regulatory submissions run parallel with, and will ultimately replace, single-use documents. Here, Adnan Jamil, a Senior Consultant at data-driven life sciences transformation specialist, Iperion, offers step-by-step advice to… Read More

#Exclusive Content #News

#Bioscience #Drug development #Drug discovery

Taconic Biosciences launches TruIMPORT importation solution

Taconic Biosciences has launched a new solution, TruIMPORT, for importing genetically engineered models from China into academia vivarium without quarantine, in collaboration with Cyagen. Researchers at non-profit institutions play a critical role in drug discovery; however, outsourcing animal model generation can be cost prohibitive or a logistical challenge. Hurdles in… Read More

#News

#Alzheimer's #Drug development #Drug discovery #FDA #Research

Historic breakthrough in the treatment of Alzheimer’s

The US Food and Drug Administration (FDA) has approved Biogen’s regulatory application for the use of aducanumab in the treatment of Alzheimer’s disease, which removes amyloid from brains. Aducanumab is the first new Alzheimer’s drug in nearly 20 years, and there is reportedly mixed evidence over its efficacy. However, according… Read More

#News

#Biology #Biotechnology #Drug development #Drug discovery #Life sciences #SLAS 2021

Poster award deadlines approaching for SLAS 2021

The deadlines for the Tony B. Academic Award and the Student Poster Award for SLAS Europe 2021 is June 14, a week prior to the conference, which takes place June 23-25 digitally. SLAS’ call for poster abstracts provide opportunities to receive recognition, experience and praise for original research by a… Read More

#News

#Assay #Bioscience #Drug development #Kinetics #Video

Re-energise your kinase discovery programme

Using Promega’s NanoBRET technology, scientists at Aurelia Bioscience have implemented intracellular kinase assays designed to study the interaction of compounds on kinase targets in intact living cells. Advantages of this technique include examination of compound binding to target kinases at physiological ATP concentrations, expression of full-length kinase target… Read More

#Videos

#Covid-19 #Drug development #Immunology / Virology & Vaccines

Is a needle-free Covid-19 vaccination possible?

University of Queensland scientists have successfully protected mice from the Covid-19 virus by administering a US-developed vaccine candidate with a ‘patch’, rather than a needle. The University of Texas Hexapro vaccine candidate, delivered via the UQ-developed and Vaxxas-commercialised high-density microarray patch (HD-MAP), provided protection against Covid-19 disease with a single,… Read More

#Covid-19 #News #Trending News

#Clinical trial #Diabetes #Drug development #GlobalData #Type 2 diabetes

Eli Lilly’s tirzepatide continues to outperform popular diabetes drugs

Eli Lilly’s tirzepatide, a once-weekly dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 receptor agonist (GLP-1RA), recently demonstrated that it was able to not only reduce HbA1c levels in type 2 diabetes (T2D) patients, but also confer weight loss when compared to insulin glargine in the SURPASS-4 trial. Tirzepatide… Read More

#News #Trends & Analysis

#Cancer immunotherapy #Cancer research #Drug development

Are women less susceptible to some skin cancers?

Women may have a stronger immune response to a common form of skin cancer than men, according to early research on mice and human cells. Led by University of Manchester scientists at the Cancer Research UK Manchester Institute, the team publish their findings in Clinical Cancer Research. Men have more… Read More

#Cancer Research #News #Trending News

#Drug delivery #Drug development #Immunology / Virology & Vaccines #mRNA #Vaccines

Samsung Biologics adds mRNA vaccine manufacturing to its services

Samsung Biologics, a CDMO, plans to add mRNA vaccine drug substance (DS) manufacturing capability to its current facility in Songdo, ready for cGMP operations within early 2022. mRNA has been the technology of choice for many Covid-19 vaccines due to its characteristics of safety and fast scalability in manufacturing. “We… Read More

#News

#Antibodies #Drug development #Life sciences

Picking the right custom antibody provider

Selecting the right custom antibody provider for a project is an important decision. It can mean the difference between a breakthrough or failure. It is therefore important where and how antibodies are made. With this infographic, available for free download, you will learn what sets Fortis Life Science’s Bethyl… Read More

#Editor's Choice #News